Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Gilead (GILD) announced that the FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with extensive-stage small cell lung cancer, or ES-SCLC ...

Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified the company’s overall business. However, the Cell Therapy franchise ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab govitecan-hziy), has been granted a second Breakthrough Therapy designation by ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...

The FDA has granted Breakthrough Therapy Designation (BTD) to Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose ...